PD-L1

[Merck] Merck announced that the Phase III KEYNOTE-091 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.

[Translational Oncology] Investigators suggested that stiffer substrate enhanced melanoma development by upregulating SNF5 expression, and SNF5 was a key mediator of stiffer matrix-induced immune evasion of melanoma cancer cells.

[Journal of Clinical Oncology] The authors report the current status of first-line immunotherapy in metastatic non–small cell lung cance together with current challenges in selecting the best immunotherapeutic approach for the individual patient.

[European Journal of Pharmacology] Investigators established chemo-resistant melanoma cells and found that expression of stemness genes were upregulated in the resistant melanoma cells. And Astragalus polysaccharide could downregulate expression of stemness genes.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated that teprotumumab, an anti-insulin-like growth factor I receptor inhibitor, attenuated constitutive expression and induction by the thyroid-stimulating hormone of MHC II and these B7 members in CD34+ fibrocytes.

[NaNotics LLC (BusinessWire, Inc.)] NaNotics LLC announced a research collaboration with Mayo Clinic to develop a NaNot that targets the soluble form of PD-L1, a tumor-generated immune inhibitor.